Mechanism of action
Clonidine is a selective alpha-2 adrenergic receptor agonist that acts primarily in the central nervous system. It stimulates alpha-2A receptors in the rostral ventrolateral medulla and locus coeruleus, reducing sympathetic outflow from the CNS and decreasing peripheral vascular resistance, heart rate, and blood pressure.
Central effects:
- Activates presynaptic alpha-2 receptors in the brainstem, causing negative feedback inhibition of norepinephrine release
- Reduces sympathetic tone to the heart and peripheral vasculature
- Decreases plasma renin activity
Peripheral effects:
- At high doses, can stimulate peripheral postsynaptic alpha-2 receptors, causing initial vasoconstriction and transient blood pressure elevation
- This explains the paradoxical brief hypertension seen with IV administration
The net result is decreased cardiac output, heart rate, systemic vascular resistance, and blood pressure. In ADHD, clonidine enhances prefrontal cortex function by strengthening postsynaptic alpha-2A receptor signaling, improving working memory and impulse control.
- Clonidine is a centrally acting alpha-2 agonist that reduces sympathetic outflow, lowering BP and heart rate.
- Abrupt discontinuation causes rebound hypertension (most testable adverse effect); always taper over 2-4 days.
- Indications: hypertension, ADHD, opioid/alcohol withdrawal, Tourette syndrome, menopausal hot flashes.
- Paradoxical initial hypertension can occur with IV administration due to peripheral alpha-2 receptor stimulation.
- Tricyclic antidepressants (TCAs) block alpha-2 receptors and antagonize clonidine's antihypertensive effect.
- Clonidine suppression test: used to diagnose pheochromocytoma (catecholamines remain elevated despite clonidine).
- Common side effects: dry mouth (40%), sedation, bradycardia, orthostatic hypotension, constipation.
- When discontinuing both clonidine and a beta-blocker, stop the beta-blocker first to avoid severe rebound hypertension from unopposed alpha stimulation.
Indications
FDA-approved uses:
- Hypertension (monotherapy or combination therapy)
- Attention-deficit/hyperactivity disorder (ADHD) as monotherapy or adjunct to stimulants
- Epidural administration for severe cancer pain unresponsive to opioids
Off-label uses:
- Opioid, alcohol, and nicotine withdrawal (suppresses sympathetic hyperactivity)
- Tourette syndrome and tic disorders
- Menopausal hot flashes
- Restless leg syndrome
- Clozapine-induced sialorrhea
- Hypertensive urgency (not emergency)
- Diagnostic test for growth hormone deficiency
- Prevention of migraines (prophylaxis)
Clonidine is particularly useful in ADHD patients with comorbid tics, aggression, or insomnia, where stimulants may be problematic. In opioid withdrawal, it specifically addresses the autonomic symptoms (hypertension, tachycardia, sweating, lacrimation) but does not reduce cravings.
Pharmacokinetics
Absorption:
- Oral bioavailability: 75-95%
- Peak plasma concentration: 3-5 hours after oral dose
- Transdermal patch provides steady-state levels in 2-3 days
Distribution:
- Lipophilic, crosses blood-brain barrier readily
- Volume of distribution: 2.1 L/kg
- Protein binding: 20-40%
Metabolism:
- Hepatic metabolism via CYP2D6 (minor pathway)
- Approximately 50% metabolized, 50% excreted unchanged
Elimination:
- Half-life: 12-16 hours (oral), up to 41 hours (transdermal)
- Primarily renal excretion (65% unchanged in urine)
- Dose adjustment required in renal impairment
Available formulations:
- Immediate-release tablets
- Extended-release tablets (for ADHD)
- Transdermal patches (changed weekly)
- Injectable solution (epidural use)
The transdermal formulation improves adherence and provides stable plasma levels, reducing peaks and troughs associated with oral dosing. However, skin irritation occurs in 20-40% of patients using patches.
Adverse effects
Most common (>10%):
- Dry mouth (xerostomia) — most frequent, occurs in 40% of patients
- Drowsiness and sedation — dose-dependent, often improves with time
- Dizziness and orthostatic hypotension
- Constipation
- Fatigue
Cardiovascular:
- Bradycardia (can be pronounced, especially with IV administration)
- Rebound hypertension — critical adverse effect with abrupt discontinuation; blood pressure may exceed pretreatment levels, potentially causing hypertensive crisis
- AV block (especially in patients with preexisting conduction abnormalities)
- Orthostatic hypotension
Central nervous system:
- Sedation (limits use in some patients)
- Depression
- Vivid dreams or nightmares
- Headache
Dermatologic:
- Contact dermatitis with transdermal patches (occurs in 20-40%)
- Localized erythema and pruritus at patch site
Metabolic:
- Sodium and water retention (may require diuretic)
- Weight gain
- Glucose intolerance (rare)
Other:
- Sexual dysfunction (erectile dysfunction, decreased libido)
- Withdrawal syndrome if stopped abruptly: hypertension, tachycardia, tremor, anxiety, headache
Pediatric considerations:
- Children may experience more pronounced sedation
- Growth should be monitored in children on long-term therapy
Contraindications and warnings
Absolute contraindications:
- Hypersensitivity to clonidine or any component
- Epidural clonidine is contraindicated in patients on anticoagulation or with bleeding disorders, or infection at injection site
Relative contraindications and warnings:
- Sick sinus syndrome or severe bradycardia
- Second- or third-degree AV block (without pacemaker)
- Recent myocardial infarction
- Cerebrovascular disease
- Severe coronary insufficiency
- Raynaud disease or thromboangiitis obliterans
Black box warning:
- Epidural clonidine: Risk of severe hypotension, especially in patients already on antihypertensives
Critical clinical warnings:
Rebound hypertension
Abrupt discontinuation causes potentially life-threatening rebound hypertension, typically occurring 18-72 hours after the last dose. Taper gradually over 2-4 days when discontinuing. If surgery is planned, continue clonidine perioperatively or substitute with another antihypertensive.
Sedation and CNS depression
May impair mental and physical abilities. Caution patients about operating machinery or driving. Risk is increased with concomitant CNS depressants.
Pregnancy and lactation
- Pregnancy category C
- Crosses the placenta; limited human data
- Excreted in breast milk; use with caution in nursing mothers
Special populations:
- Elderly: Increased risk of orthostatic hypotension and falls; start with lower doses
- Renal impairment: Dose reduction required; monitor carefully
- Hepatic impairment: Use with caution, although metabolism is not primarily hepatic
Drug interactions
Pharmacodynamic interactions:
CNS depressants
Alcohol, benzodiazepines, opioids, barbiturates, and sedative antihistamines potentiate sedation. Avoid concurrent use or reduce doses of both agents.
Antihypertensive agents
Additive hypotensive effects with beta-blockers, calcium channel blockers, diuretics, and ACE inhibitors. Beta-blockers may exacerbate rebound hypertension if clonidine is discontinued; when discontinuing both, withdraw the beta-blocker first, several days before gradually tapering clonidine, to avoid unopposed alpha-mediated severe rebound hypertension.
Tricyclic antidepressants (TCAs)
TCAs (especially imipramine and desipramine) may reduce the antihypertensive effect of clonidine by blocking alpha-2 receptors. Monitor blood pressure closely.
Other alpha-2 agonists
Additive effects with other centrally acting agents (methyldopa, guanfacine). May increase risk of bradycardia and hypotension.
Pharmacokinetic interactions:
CYP2D6 interactions
Clonidine is a minor substrate of CYP2D6. Strong CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine) may increase clonidine levels, though clinical significance is limited.
Other notable interactions:
- Prazosin and other alpha-1 blockers: May reduce effectiveness of clonidine
- Stimulants: Amphetamines and methylphenidate may counteract clonidine's antihypertensive effect but are commonly co-prescribed for ADHD with appropriate monitoring
- Verapamil and diltiazem: Increased risk of AV block and bradycardia
- Digoxin: Additive bradycardia; monitor heart rate
Clinical pearls
High-yield clinical tips:
- Rebound hypertension is the most important adverse effect to remember. Always taper clonidine gradually; never stop abruptly. If a patient presents with hypertensive crisis, ask about recent clonidine discontinuation.
- Transdermal patches should be applied to hairless skin on the upper arm or chest. Rotate sites to minimize dermatitis. The patch continues to deliver drug for about 8 hours after removal.
- Clonidine suppression test is used to diagnose pheochromocytoma. In normal individuals, clonidine suppresses catecholamine release; in pheochromocytoma, catecholamines remain elevated.
- Paradoxical hypertension can occur with initial IV doses due to peripheral alpha-2 receptor stimulation before central effects predominate. This is why oral dosing is preferred for routine hypertension.
- For opioid withdrawal, clonidine treats the autonomic symptoms (hypertension, tachycardia, diaphoresis) but does not reduce cravings or prevent relapse. It is often combined with buprenorphine or methadone for comprehensive treatment.
- ADHD dosing: Extended-release formulations are preferred. Clonidine is particularly useful for hyperactivity, impulsivity, and sleep disturbances. Sedation typically improves after 2-4 weeks.
- Combination with beta-blockers: If both must be discontinued, stop the beta-blocker first, then taper clonidine several days later to prevent unopposed alpha-adrenergic vasoconstriction.
- Dry mouth management: Encourage sugar-free gum, frequent sips of water, and good oral hygiene to prevent dental caries.
- Clonidine has no significant effect on lipids or glucose (unlike some beta-blockers and diuretics), making it useful in patients with metabolic syndrome, though it may cause mild sodium retention.
- In hypertensive urgency (not emergency), oral clonidine can provide gradual blood pressure reduction. However, abrupt reduction should be avoided in chronic hypertension to prevent end-organ hypoperfusion.
CLONIDINE for withdrawal symptoms: Cramps Less, Opioid Nausea Improves, Diaphoresis Improves, Insomnia reduced, No Euphoria (doesn't treat cravings), Eyes (lacrimation) improve.
Practice questions
1. A 58-year-old man with hypertension presents to the emergency department with severe headache, diaphoresis, and blood pressure of 210/120 mmHg. He ran out of his blood pressure medication 2 days ago. His home medications include clonidine, lisinopril, and hydrochlorothiazide. Physical exam shows anxiety, tremor, and tachycardia. Which medication is most likely responsible for his presentation?
2. A 35-year-old woman with opioid use disorder is started on clonidine to manage withdrawal symptoms. On day 3 of treatment, she reports that her blood pressure, sweating, and tremor have improved significantly, but she still has intense cravings for opioids and feels anxious. Which of the following best explains her persistent symptoms?
3. A 45-year-old man with hypertension controlled on clonidine and metoprolol is scheduled for elective surgery. The surgical team plans to hold all antihypertensive medications on the day of surgery. Which of the following is the most appropriate management of this patient's medications?
Frequently asked questions
How does clonidine work?
Clonidine stimulates alpha-2 adrenergic receptors in the brainstem, reducing sympathetic nervous system outflow from the central nervous system. This results in decreased peripheral vascular resistance, heart rate, and blood pressure. It also reduces norepinephrine release through negative feedback inhibition at presynaptic receptors.
What are the side effects of clonidine?
The most common side effects are dry mouth (40% of patients), drowsiness, dizziness, constipation, and fatigue. Cardiovascular effects include bradycardia and orthostatic hypotension. The most serious adverse effect is rebound hypertension, which occurs if clonidine is stopped abruptly. Transdermal patches commonly cause contact dermatitis at the application site.
Is clonidine a controlled substance?
No, clonidine is not a controlled substance in the United States or most other countries. It is a prescription medication but is not classified as having abuse potential by the DEA. While it does not produce euphoria, abrupt discontinuation causes a withdrawal syndrome characterized by rebound hypertension rather than drug-seeking behavior.
What is clonidine used for?
Clonidine is FDA-approved for hypertension, ADHD, and severe cancer pain (epidural route). It is widely used off-label for opioid and alcohol withdrawal, Tourette syndrome, menopausal hot flashes, and migraine prophylaxis. In ADHD, it is especially useful for patients with comorbid tics, aggression, or insomnia. In opioid withdrawal, it suppresses autonomic hyperactivity symptoms.
Clonidine vs guanfacine — what is the difference?
Both are alpha-2 agonists used for hypertension and ADHD, but guanfacine is more selective for alpha-2A receptors and has less sedation. Guanfacine has a longer half-life (17 hours vs 12-16 hours) and may be better tolerated in children. Clonidine causes more dry mouth and drowsiness but has stronger antihypertensive effects. Both require gradual tapering to avoid rebound hypertension.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: C02AC01WHO ATC/DDD index: N02CX02
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.